Eli Lilly Inks Up to $1.9B Gene-Editing Deal for Rare Kidney Diseases
LLY•Eli Lilly has secured an up-to-$1.9 billion licensing agreement with Ascidian Therapeutics for its gene-editing platform to develop therapies for rare inherited kidney diseases. The deal grants Lilly exclusive rights through discovery and clinical development, with milestone payments and royalties tied to approvals and product sales.
1. Licensing Agreement Details
Under the up-to-$1.9 billion agreement, Lilly acquires exclusive development and commercialization rights to Ascidian’s gene-editing platform for novel therapies addressing rare inherited kidney diseases. The package encompasses payments upon signing, development and regulatory milestones, plus tiered royalties on eventual sales.
2. Pipeline and Strategic Impact
This collaboration expands Lilly’s nephrology pipeline into precision genetic medicine, aiming to address disorders with high unmet need. By leveraging Ascidian’s technology, Lilly positions itself to accelerate clinical timelines and capture market share in emerging kidney-disease treatments.
